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ABSTRACT
Introduction: Guillain Barre syndrome (GBS) is a rare autoimmune neurological disorder in which
the body’s immune system attacks part of its peripheral nervous system resulting in limb and cranial
nerve weakness often with respiratory compromise and limitation on physical function. The
worldwide incidence of GBS ranges from 0.81 to 1.89 cases per 100000 person-years. Various factors
such as age, symptoms and disease form that influence the outcome of GBS have been previously
studied. This study seeks the additional fundamental knowledge of the factors affecting clinical
management and the outcome in patients with GBS.
Objective: To identify factors affecting clinical management and the outcomes in patients with GBS
Method: A retrospective observational study was conducted in tertiary care teaching hospital of
Southern India. Institutional Ethics Committee approval was obtained prior to the study. GBS patients
admitted between January 2014 to December 2019 were identified from Medical Record Department
(MRD) patient files using International Classification of Diseases (ICD) code G61.0. Patient
information on demographic, medical history, medication history, laboratory parameters,
electrophysiological data, type of GBS, duration of hospitalization and drug treatment were retrieved
from medical records. Factors associated with outcome were identified by multiple logistic regression
and odds ratio (OR) was calculated.
Results: Based on inclusion and exclusion criteria, 212 cases of GBS were included in the study. The
mean age of the GBS patients was 39.92 ±20.09 years and majority of the patients were male (n=142,
67%). The most commonly prescribed regimen was Intravenous Immunoglobulin (IVIgG) plus
physiotherapy/occupational therapy (n=79, 37.3%) in which 74 (93.7%) patients showed
improvement. Patients with Acute Motor and Sensory Axonal Neuropathy (AMSAN) variant
(Adjusted OR=2.652; 95% CI 0.677-10.393), hypertension (Adjusted OR=2.839 95% CI 0.9868.175), who consume alcohol (Adjusted OR=4.457; 95% CI 1.342-14.799), developed sepsis
(Adjusted OR= 8.685 95% CI 1.556-48.471), cardiac arrest (Adjusted OR= 6.020 95% CI 0.83543.401)and were ventilated (Adjusted OR= 2.319 95% CI 0.739-7.277) were associated with risk of
poor outcome. Whereas those with Miller Fisher Syndrome (MFS) variant (Adjusted OR=0.144; 95%
CI 0.009-2.205) and diabetes mellitus (Adjusted OR=0.464 95% CI 0.135-1.587) showed better
outcome.
Conclusion: It was found that alcoholism, history of hypertension, development of sepsis and cardiac
arrest, requirement of mechanical ventilation and AMSAN variant of GBS were potential risk factors
for poor outcome in GBS patients. MFS variant and history of Diabetes mellitus were found to have
a protective effect against the same.
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INTRODUCTION
1. Introduction
Guillain Barre syndrome (GBS) is a rare autoimmune neurological disorder in which the body’s
immune system attacks part of its peripheral nervous system resulting in limb and cranial nerve
weakness often with respiratory compromise and limitation on physical function. [1]
In 19th century there were cases of rapidly progressive weakness that may have been acute
inflammatory neuropathy. These cases were further studied by Guillain, Barre and Strohl in 1916,
by careful interpretation of motor polyradiculoneuritis and characteristic albuminocytologic
dissociation in cerebrospinal fluid, and thus justified their inclusion in its name. [2]

2. Epidemiology
The worldwide incidence of GBS ranges from 0.81 to 1.89 cases per 100000 person-years. [1] The
male to female ratio of the disease is 1.25:1. Although GBS affects all ages, but a bimodal peak is
observed which represents young adults and elderly. [4] It is lower in children at 0.34 to 1.34 per
100000 and increases after age 50 years from 1.7 to 3.3 per 100000. [3]
The incidence is increasing every year, however may vary based on quality of surveillance and
geographical prevalence of causal factors.

3. Etiology
GBS may be preceded by gastrointestinal or respiratory infection weeks prior to its onset. This
may be caused by bacterial (Campylobacter jejuni, Mycoplasma pneumoniae) or viral
(Cytomegalovirus, Epstein-Barr virus) infection.
GBS may also been triggered by vaccination, underlying disease, surgery, certain malignancies,
pregnancy, trauma and tissue transplantation.[5]

4. Pathophysiology
GBS results from an immune response that mistakenly attacks the hosts nerve tissue by
recognizing a molecular similar epitope mechanism (molecular mimicry) [5] i.e. complement
fixation of antibodies against peripheral nerve gangliocytes resulting in autoimmune nerve injury.
The subtype and severity of the syndrome are partly determined by the nature of the preceding
infection and specificity of such antibodies.
In case of bacterial infection, the walls of the bacteria contain ganglioside like epitopes that trigger
antibody response in patients with GBS.[6]
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5. Diagnosis
The most commonly used diagnostic criteria for GBS was developed by the National Institute of
Neurological Disorders and Stroke (NINDS) in 1978. It is preferred by the clinicians as it includes
the clinical features of typical and atypical types of GBS.
Lumbar puncture is done to obtain the cerebrospinal fluid. The CSF examination typically shows
albuminocytological dissociation i.e. increase in protein or albumin level without increase in CSF cell
count.
In addition, nerve conduction studies and electromyography can be done to assess nerve and muscle
function. They are normal in early stage but show typical changes after a week or so with conduction
block and multifocal motor slowing.
Further investigative procedures can be done to identify underlying cause and exclude diseases that
mimic GBS:
-Chest X-ray, stool culture and immunological tests to rule out presence of cytomegalovirus,
mycoplasma, zika virus, C. jejuni etc.
-Antibodies to gangliosides
MRI can be helpful for excluding differential diagnosis. The presence of nerve root enhancement on
gadolinium-enhanced MRI is a sensitive feature of GBS, and can be useful in diagnosis, especially in
children where other diagnostic measures can be challenging.
Ultrasound imaging of peripheral nerve reveals enlarged cervical nerve roots early in the disease
course. This is a new diagnostic tool in GBS which helps in the early detection of the disease, but
further validation is required. [9]

6. Variants
6.1 Acute inflammatory demyelinating polyneuropathy (AIDP)
The immune response damages the myelin coating and therefore interferes with the transmission of
nerve signal.
The activated CD4 T-helper cells bind to specific antigen on myelin-producing Schwann cells or on
myelin sheath itself [7], releasing cytokines which activate B-cell and macrophages. B-cell produce
antibodies that mark the auto-antigen. Macrophages use those antibody markers to bind to and strip
the myelin.
Patients with AIDP typically present with paraesthesia, muscle weakness and areflexia/hyporeflexia
if motor nerves are affected; double vision and difficulty speaking if cranial nerves are involved;
diaphragmatic muscle weakness; heart rate and blood pressure fluctuations, constipation, urinary
retention in case of autonomic instability.
Nerve conduction studies (NCS) may show evidence of demyelination with distal latency
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prolongation and conduction velocity slowing or blocked. This may be accompanied by temporal
dispersion of compound muscle action potential (CMAP) configuration, giving the appearance of
prolonged F-wave latencies. Sensory nerve studies may be abnormal- response at the hand more
affected than those at the foot. [7,8]

6.2 Acute motor axonal neuropathy (AMAN)
In this the axon themselves are damaged by immune response.
AMAN is often associated to prior C. jejuni infection. The body produces antibodies against
lipopolysaccharides on the bacterial membrane. These antibodies cross-react with the gangliosides at
the node of Ranvier beneath the intact Schwann cells; gangliosides involved are GM1, GD1a,
Ga1Nac-GD1a and GM1b. This leads to complement activation and macrophage invasion causing
disruption of ion channel and blockade of conduction.
The patients present with symptoms similar to AIDP without sensory involvement. They manifest
rapidly progressive weakness including craniobulbar and respiratory function.
NCS shows evidence of CAMP amplitude loss without demyelination features with normal sensory
nerve action potential (SNAP).

6.3 Acute motor and sensory axonal neuropathy (AMSAN)
Similar to AMAN with ventral nerve root, dorsal nerve root and sensory fibre involvement.
Gangliosides involved are GM1, GD1a and GM1b.
The patients present with symptoms similar to AIDP but with poor prognosis.
NCS shows evidence of severe axon loss of sensory and motor fibres without demyelinating features.
[8]

6.4 Miller-fisher syndrome (MFS)
Involves the presence of GQ1b antigen on oculomotor nerves, sensory nerves, cerebellar neurons and
cell-membrane of C. jejuni. Antibodies to this ganglioside inhibit synaptic transmission at the motor
nerve terminals.
The patients present with ophthalmoplegia, ataxia and areflexia. Unilateral or bilateral facial
weakness, dysphagia, dysarthria, abnormal pupillary reactivity and extremity weakness may also be
seen.
NCS may show evidence of patchy loss of SNAP amplitude in the arm and leg without significant
abnormalities along motor nerve trunks. They may also be loss of facial motor CMAP amplitudes
and abnormalities of blink reflexes.[8]
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7. Treatment
The cornerstone of therapy in GBS is IVIg and plasmapheresis.
Although IVIg is preferred over plasmapheresis due to its easy availability and greater convenience
both are equally effective. However, the combination is not significantly superior over individual
treatment options.
IVIg are dosed as 0.4gm/kg/day (2gm/day) for 5 consecutive days whereas plasmapheresis is
performed 5 times on alternative days or during 2week with total 5 plasma volume exchange.
Corticosteroid monotherapy is not effective for treatment of GBS nevertheless short-term benefits,
when combined IVIg therapy are noted.
Eculizumab, a monoclonal antibody was studied during a small randomized controlled trial (Japanese
Eculizumab Trialist) where it did not show differences in primary end-points but they concluded it
was an effective therapy for GBS. [11]
Physiotherapy should be started earlier during the course of the disease as it has shown to significantly
improve muscle strength, functional ability and fatigue. [12] In case of severe fatigue a physical
training program should be considered. Rehabilitation program should be started as soon as the patient
begins to improve.
GBS patients who are symptomatic should be carefully observed for any fluctuations in blood
pressure or heart rate, clinical signs of respiratory failure that may be signs of disease progression,
and these should be managed at specialized centres. [13]
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NEED FOR THE STUDY
Need: GBS is a rare and important life-threatening disease that affects all age groups and gender.
There are currently two treatments commonly used: plasmapheresis and high dose iv immunoglobulin
G therapy that provide significant recovery for GBS. These therapies are costly and the cost increases
with increase in severity- where the patient would need intensive medical care at that stage. Despite
intensive care management of the patients with advanced form of GBS, the mortality and morbidity
remain high. Various factors that influence the outcome of GBS have been previously studied. Patient
age, symptoms and disease form influence the outcome whereas treatment method did not
significantly influence the outcome. [14] This study seeks the additional fundamental knowledge of
the factors affecting clinical management and the outcome in patients with GBS so as to reduce the
burden of neurological disorders.
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OBJECTIVES
General objective:


To identify factors affecting clinical management and the outcomes in patients with GBS

Specific objectives:


To know the in-hospital prevalence of GBS.



To study the clinical presentation & subtypes of GBS.



To know the socio-demographic characteristics of GBS patients



To know the co-morbid conditions, present in GBS patients



To identify the complications that occur in GBS patients.



To identify the risk factors affecting clinical management and outcome in patients with GBS using
multiple logistic regression.
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METHODOLOGY
Study site: Tertiary care teaching hospital in Southern India.

Study design: Retrospective observational study.

Study period: 12 months (Data collected from Jan 2014 till Dec 2019)

Ethical clearance: Was obtained from the Institutional Ethical Committee, Kasturba Hospital,
Manipal University, Manipal.

Sample size: 212 GBS cases diagnosed and admitted during Jan 2014 to Dec 2019

Study criteria:
Inclusion: All the patients admitted to intensive care units, medical wards and neurological wards of
Kasturba Hospital, Manipal diagnosed with GBS.
Exclusion:
• Acute myelopathy
• Vasculitic neuropathy
• Myasthenia gravis
• Acute pharyngeal cervicobrachial neuropathy (APCBN)
• Botulism
• West Nile encephalomyelitis
• Amyotrophic lateral sclerosis (ALS)
• Diabetic polyneuropathy (DPN)
• Poliomyelitis
• Toxic neuropathy

Sources of data collection: Patient case records

Materials used: Case Record Form (CRF)
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Operational modality
Identification of patient: GBS cases were identified from medical record department using ICD
code G61.0.

Collection of Data:
Guillain Barre Syndrome (GBS) patients admitted during Jan 2014 to Dec 2019 were identified from
MRD registry using ICD code G61.0. GBS patients who have fulfilled the inclusion criteria were
selected and the following information was collected:
- Demographical data, clinical data, laboratory parameters, electrophysiology, medication history,
comorbid conditions, type of GBS, treatment during hospital stay and outcomes

Interpretation of data:
- The data collected was analyzed to identify the factors that were correlated with the clinical
management and outcome

Statistical Analysis:
Continuous data was expressed as mean ± SD. Nominal data was described and expressed in
frequency and percentage. Univariate analysis was used to identify the risk factors affecting the
clinical management and outcomes in patients with GBS, and calculation of unadjusted odds ratio.
Odds ratio is a measure of the association between risk factors and outcome (not-improved). The
factors identified in univariate analysis with p<0.25 were selected and taken for multiple logistic
regression for calculation of p value and adjusted odds ratio. Data entry and statistical analysis were
done using IBM SPSS software version 20.0.
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RESULTS

A total of 254 patient records were identified with a confirmed diagnosis of GBS over a period of 6
years from January 2014 to December 2019 in Kasturba Hospital, Manipal. Among them 212 cases
were included and the rest 42 were not considered either due to exclusion criteria or missing records.

1. Demographic and social characteristics of study population
The demographic and social characteristic of the study population are described in Table 1. The mean
age of the GBS patients was 39.92 ±20.09 years. Majority of patients were in the age category of 3060 years (n=104, 49.1%). In our study population majority of the patients were male (n=142, 67%).
Alcohol consumption, smoking and tobacco use was observed in 24 (11.3%), 13 (6.1%) and 9 (4.2%)
patients respectively.
In our study, majority of the patients (n=51, 24.1%) were include in services category such as
company employees, teachers, bank employees, healthcare service etc.
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Table 1: Demographic and social characteristics of study population
Parameter

Frequency (%)

Age (mean ± SD)

39.92 ± 20.09141

Age category


<30



68 (32.1%)



30-60



104 (49.1%)



>60



40 (18.9%)



Male



142 (67%)



Female



70 (33%)

Gender

Duration of hospitalization


(mean ± SD)



16.49 ± 19.35120



(median ± IQR)



10.5 ± 10.75

Alcoholism


Yes



24 (11.3%)



No



188 (88.7%)

Smoking


Yes



13 (6.1%)



No



199 (93.9%)

Tobacco use


Yes



9 (4.2%)



No



203 (95.8%)

Occupation


Student



41 (19.3%)



Farmer



30 (14.2%)



Service



51 (24.1%)



Housewife



39 (18.4%)



Cooly



19 (9%)



Fishing



4 (1.9%)



Labour



4 (1.9%)



No occupation



24 (11.3%)
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2. Types, complication and clinical outcomes of GBS
Types and complication of GBS and clinical outcomes in GBS patients are described in Table 2.
AIDP was found to be the most common variant among the GBS patients (n=136, 64.2%). Total of
40 (18.9%) patients suffered from respiratory paralysis due to the disease. Out of 212 patients, 168
(79.2%) patients showed improvement whereas the remaining 44 (20.8%) did not show any
improvement.

Table 2: Types, complications and clinical outcomes of GBS
Parameter

Frequency

Types of GBS


AIDP



136 (64.2%)



AMAN



31 (14.6%)



AMSAN



14 (6.6%)



MFS



16 (7.5%)



UNKNOWN



15 (7.1%)

Complications


Respiratory paralysis



40 (18.9%)



Sepsis



12 (5.7%)



Pulmonary embolism



3 (1.4%)



Cardiac arrest



9 (4.2%)



Others



26 (12.3%)

Clinical outcome


Unchanged



6 (2.8%)



Improved



164 (77.4%)



Recovered



4 (1.9%)



Worsened



1 (0.5%)



Expired



7 (3.3%)



DAMA



30 (14.2%)

29

3. Signs and symptoms of GBS based on Diagnostic criteria
The signs and symptoms based on Diagnostic criteria for GBS published in Annals of Neurology as
requested by NINDS in 1978 are given in Table 3. Progression of symptoms over days to 4weeks and
Relative symmetry (n=206, 97.2%) were observed in most patients followed by Areflexia or
hyporeflexia (n=203, 95.8%) and positive EMG/nerve conduction velocity studies (n=174, 82.1%)
and Progressive weakness in both arms and legs (n=161, 75.9%).

Table 3: Signs and symptoms of GBS based on Diagnostic criteria
Signs and symptoms

Frequency (%)

Progressive weakness in both arms and legs

161 (75.9%)

Areflexia or hyporeflexia

203 (95.8%)

Progression of symptoms over days to 4weeks

206 (97.2%)

Relative symmetry

206 (97.2%)

Mild sensory signs and symptoms

73 (34.4%)

Cranial nerve involvement, especially bilateral facial weakness

81 (38.2%)

Recovery beginning 2 to 4 weeks after progression ceases

1 (0.5%)

Autonomic dysfunction

76 (35.8%)

Absence of fever at onset

147 (69.3%)

Typical CSF (albuminocytologic dissociation)

92 (43.4%)

EMG/nerve conduction velocity studies (characteristic signs of

174 (82.1%)

demyelinating process in the peripheral nerves)
Asymmetrical weakness

3 (1.4%)
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4. Possible etiological factors of GBS
Possible etiological factors of GBS are described in Table 4. Diarrhoea (n=29, 13.7%) was found to
be the most common etiological factor among GBS patients studied followed by pesticide exposure
(n=28, 13.2%) and vaccine (n=26, 12.3%)

Table 4: Possible etiological factors of GBS
Possible etiological factors

Frequency (%)

Viral infection

12 (5.7%)

Vaccine

26 (12.3%)

Bacteria

1 (0.5%)

Diarrhoea

29 (13.7%)

Surgery

10 (4.7%)

Pesticide exposure

28 (13.2%)
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5. Comorbidities
The comorbid conditions in the GBS patients are given in Table 5. Hypertension (n=38, 17.9%) and
diabetes (n=32, 15.1%) were the most common comorbid observed in GBS patients.

Table 5: Comorbidities
Disease/Conditions

Frequency (%)

Hypertension

38 (17.9%)

Diabetes

32 (15.1%)

Ischemic Heart Disease

5 (2.4%)

Rheumatoid Heart Disease

1 (0.5%)

Respiratory Tract Infection

3 (1.4%)

Thyroid disorders

3 (1.4%)

Bronchial asthma

7 (3.3%)

Dyslipidaemia

2 (0.9%)

Epilepsy

2 (0.9%)

Tuberculosis

1 (0.5%)

32

6. Treatment in GBS
Different treatment regimens that are given to the patients are shown in Table 6. The most commonly
prescribed regimen was IVIgG plus physiotherapy/occupational therapy (n=79, 37.3%) in which 74
(93.7%) patients showed improvement, followed by physiotherapy/occupational therapy (n=32,
15.1%) in which 26 (81.3%) patients showed improvement and IVIgG + Physiotherapy/occupational
therapy + Corticosteroids (n=18, 8.5%) in which 16(88.9%) patients showed improvement.
Most of the patients who did not opt to take any therapy (n=34, 16.0%) were discharged against
medical advice (n=22, 64.7%) and few of them (n=11, 32.4%) showed improvement in their
symptoms with time.

Table 6: Treatment in GBS
Types of treatment

Frequency (%)

IMPROVED

NOT IMPROVED

A only

12 (5.7%)

11 (91.7%)

1 (8.3%)

A+B

79 (37.3%)

74 (93.7%)

5 (6.3%)

A+C

3 (1.4%)

3 (100%)

0

A+B+C

18 (8.5%)

16 (88.9%)

2 (11.1%)

D only

1 (0.5%)

0

1 (100%)

D+B

13 (6.1%)

12 (92.3%)

1 (7.7%)

D+C

1 (0.5%)

0

1 (100%)

D+B+C

4 (1.9%)

2 (50%)

2 (50%)

B only

32 (15.1%)

26 (81.3%)

6 (18.8%)

C only

5 (2.4%)

3 (60%)

2 (40%)

B+C

9 (4.2%)

9 (100%)

0

A+D+B

1 (0.5%)

1 (100%)

0

No therapy

34 (16.0%)

11 (32.4%)

23 (67.6%)

KEY:
ABCD-

IVIgG
Physiotherapy/Occupational therapy
Corticosteroids
Plasmapheresis
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7. Identification of factors affecting outcome in GBS patients by univariate analysis.
The factors that significantly affect the outcomes in GBS are given in Table 7 along with their odds
ratio and p value.

Table 7: Results of Univariate analysis of factors affecting outcome in GBS patients
Parameter

Pearson chi p value

odd ratio (95% CI)

square

Percentage
not improved

Age category


<30

8.665

0.003

0.270 (0.108-0.675)

8.8%



>60

6.083

0.014

2.549 (1.192-5.449)

35%

AMSAN

4.452

0.035

3.158 (1.034-9.640)

42.9%

MFS

2.214

0.137

0.237 (0.030-1.947)

6.2%

Smoking

9.221

0.002

5.108 (1.622-16.091)

53.8%

Alcohol

14.074

0.001

4.875 (2.010-11.823)

50%

Hypertension

7.285

0.007

2.800 (1.300-6.033)

36.8%

Diabetes

2.524

0.112

1.952 (0.846-4.501)

31.2%

Vaccine

5.151

0.023

0.133 (0.018-1.010)

3.8%

Respiratory paralysis

2.562

0.109

1.875 (0.861-4.081)

30%

Sepsis

16.302

0.001

9.111 (2.602-31.905)

66.7%

Pulmonary embolism

3.900

0.048

7.952 (0.704-89.806)

66.7%

Cardiac arrest

18.582

0.001

15.703 (3.136-78.664)

77.8%

Ventilation

8.030

0.005

2.691 (1.337-5.415)

33.9%
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8. Identification of factors affecting outcome in GBS patients by Multiple Logistic Regression.
The factors identified in univariate analysis with p <0.25 were selected and taken for multiple logistic
regression. The result of multiple logistic regression along with adjusted OR, 95% CI and p value is
presented in Table 8.
The association remain intact only with certain variables and rest may have failed to show higher
intensity of the association to odds ratio due to the presence of confounding factors.

Patients with AMSAN variant (Adjusted OR=2.652; 95% CI 0.677-10.393) of GBS had a higher risk
of poor outcome whereas those with MFS (Adjusted OR=0.144; 95% CI 0.009-2.205) variant showed
better outcome.
Patients who consume alcohol (Adjusted OR=4.457; 95% CI 1.342-14.799) were associated with risk
of poor outcome.
Patients with hypertension (Adjusted OR=2.839 95% CI 0.986-8.175) of GBS had a higher risk of
poor outcome whereas those with diabetes mellitus (Adjusted OR=0.464 95% CI 0.135-1.587)
showed better outcome.
Patients who developed sepsis (Adjusted OR= 8.685 95% CI 1.556-48.471) and cardiac arrest
(Adjusted OR= 6.020 95% CI 0.835-43.401) were associated with risk of poor outcome in GBS.
Patients who were ventilated (Adjusted OR= 2.319 95% CI 0.739-7.277) were associated with risk
of poor outcome.

Table 8: Results of Multivariate analysis of factors affecting outcome in GBS patients
Parameter

p value

Adjusted odd ratio

Percentage not

Percentage

(95% CI)

improved

improved

AMSAN

0.162

2.652 (0.677-10.393)

42.9%

57.1%

MFS

0.164

0.144 (0.009-2.205)

6.2%

93.8%

Alcohol

0.015

4.457 (1.342-14.799)

50%

50%

Hypertension

0.053

2.839 (0.986-8.175)

36.8%

63.2%

Diabetes Mellitus

0.221

0.464 (0.135-1.587)

31.2%

68.8%

Sepsis

0.014

8.685 (1.556-48.471)

66.7%

33.3%

Cardiac arrest

0.075

6.020 (0.835-43.401)

77.8%

22.2%

Ventilation

0.149

2.319 (0.739-7.277)

33.9%

66.1%
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DISCUSSION
This retrospective study performed on 212 GBS patients revealed several factors that affect outcome,
by multivariate analysis. The mean age of the GBS patients was 39.92 ±20.09 years. In our study
population majority of the patients were male (n=142, 67%).

The most commonly prescribed regimen was IVIgG plus physiotherapy/occupational therapy (n=79,
37.3%) in which 74 (93.7%) patients showed improvement.

Among the different variants of GBS, patient with AMSAN (Adjusted OR=2.652; 95% CI 0.67710.393) showed to have high risk of poor outcome whereas those with MFS (Adjusted OR=0.144;
95% CI 0.009-2.205) showed to have better outcome. Yitao Z et al. stated that among the variants of
GBS, the prognosis of MFS was the best. [22] Amin B et al. observed that AMSAN variant was
associated with the worst outcome in GBS. [23]

Alcoholism was assessed to be a potential risk factor for poor outcome in GBS patients (Adjusted
OR=4.457; 95% CI 1.342-14.799). Thomas J et al. stated that NCS conducted among chronic alcohol
abusers had higher rates of neuropathy, with 10% representing polyneuropathies. [15] Ammendola et
al showed an increased duration of alcoholism and higher total life time dose of ethanol in group with
neuropathy compared to alcoholics without neuropathy. [16]

Hypertension was found to be a risk factor for poor outcome in GBS patients (Adjusted OR=2.839
95% CI 0.986-8.175). Ferraro-Herrera AS et al. observed hypertension in 60-70% of the patients with
GBS and marked it to be a bad prognostic sign. [17] Eiben et al. noted that 60% of all GBS patients
developed hypertension with higher incidence of respiratory failure (95%) and 20% mortality rate.
[18] Gupta S et al. through univariate analysis found that cardiovascular complications including
hypertension (28.12%) was associated with poor outcome in GBs patients. [19]

Diabetes mellitus was found to be statistically significant but protective factor in the patients
(Adjusted OR=0.464 95% CI 0.135-1.587). However, Bae JS et al through multivariate analysis
identified diabetes mellitus as an independent factor for poor outcome in patients with GBS (OR=
9.049, 95% CI 2.152-38.044).[20]. In our study, most of the patients who had diabetes mellitus
received IVIg plus physiotherapy/occupational therapy, which was found to be the best possible

37

treatment as it has the highest percentage of improved patients. Hence, this may be the confounding
factor that resulted in diabetes mellitus being a protecting factor.

Sepsis was found to be a risk factor for poor outcome in patients with GBS (Adjusted OR= 8.685
95% CI 1.556-48.471). Netto A et al. stated that sepsis among other complications was considered
significant in causing death (p=0.38), Hughes scale ≤3 (p=0.015), prolonged mechanical ventilation
> 21 days (p=0.058) or prolonged hospitalization >36 days (p=0.019).[21]

Cardiac arrest was found to be a risk factor for poor outcome in patients with GBS (Adjusted
OR=6.020 95% CI 0.835-43.401). Gupta S et al. observed that 54.2% of patients developed
cardiovascular complications including cardiac arrest which showed significant association with poor
outcome as revealed by the results of univariate analysis. [19]

Mechanical ventilation was found to be a risk factor for poor outcome in patients with GBS (Adjusted
OR= 2.319 95% CI 0.739-7.277). Yitao Z et al. reported 14.4% incidence of mechanical ventilation
in patients with GBS with worse MRC score at discharge for those patients. [22]
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LIMITATIONS
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LIMITATIONS

1. The general limitations of a retrospective study apply to this study also. The residual disability
associated with GBS cannot be directly assessed.

2. Some clinical parameters which have been reported as factors affecting outcome in the previous
studies but didn’t show statistical difference in our study such as age, maybe due to confounding
factors.

3. Failure to categorize the variant of GBS in some patients due to lack of sufficient data or NCV not
conducted for some patients.
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CONCLUSION

Guillain Barre syndrome (GBS) is a rare autoimmune neurological disorder in which the body’s
immune system attacks part of its peripheral nervous system resulting in limb and cranial nerve
weakness often with respiratory compromise and limitation on physical function. In our study the
mean age of the GBS patients was 39.92 ±20.09 years and majority of the patients were male (n=142,
67%).
The most commonly prescribed regimen was IVIgG plus physiotherapy/occupational therapy (n=79,
37.3%) in which 74 (93.7%) patients showed improvement. Out of 212 GBS patients studied, 168
(79.2%) patients showed improvement whereas the remaining 44 (20.8%) did not show any
improvement.
The risk factors that resulted in poor outcome in these patients were alcohol intake, medical history
of hypertension, complications such as sepsis and cardiac arrest and mechanical ventilation support.
Also, patient with AMSAN variant of GBS showed poor outcome whereas patients with MFS variant
of GBS had better outcome. Medical history of diabetes was found to have a protective action against
poor outcome in GBS.

.
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